Drugs / mRNA-3745
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05095727 | Jun 2022 → Nov 2026 expected | glycogen storage disease Id | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-09-08 | ModernaTX, Inc. | Results Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day q4web.com ↗
Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit |
| 2021-09-09 | ModernaTX, Inc. | Regulatory Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day q4web.com ↗
The U.S. FDA has granted mRNA-3745 Orphan Drug Designation and completed its review of the IND application allowing it to proceed to clinic. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-08 | ModernaTX, Inc. | Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day q4web.com ↗ |
| 2021-09-09 | ModernaTX, Inc. | Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-3745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05095727 ↗ |
| Route | Intravenous | “intravenous (IV) administration” NCT05095727 ↗ |